$CLOV

Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value

Clover Health (CLOV) announced its 2027 Medicare Advantage plans, emphasizing PPO choice, preventive care, and member value. The plans feature low premiums, no referrals, and benefits like routine dental and vision. Clover Assistant, the company's technology, supports physicians in identifying care needs. The plans will be available to 5.2 million Medicare-eligible beneficiaries across 203 counties in five states.

Original reporting
Published Oct 1, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 12:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
4/10
AlphAI data visualization · based on globenewswire.com
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The announcement provides fresh product details but no financial guidance, limiting immediate trading relevance.

02

Market read

Provides incremental information for investors tracking Medicare Advantage providers; unlikely to trigger significant price movement.

03

What to watch

Potential regulatory scrutiny of low‑premium offerings and the need for sustained provider network support.

Relevance 4/10Novelty 3/10Timing: ahead of the 2027 enrollment period starting Oct 15

Background

Clover Health is a physician‑enablement technology firm offering Medicare Advantage PPO and HMO plans. The 2027 lineup emphasizes low‑cost options and preventive‑care benefits.

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health announced its 2027 Medicare Advantage plan lineup, including a $0‑premium PPO and expanded benefits, marking the first public disclosure of these offerings.

Expected impact

likely modest upside as investors price in expanded market coverage and competitive positioning

Evidence & confidence

The announcement adds new product information but lacks concrete financial metrics or large‑scale contracts; market reaction is expected to be limited.

Market effects

Adds competitive pressure in the Medicare Advantage space, but no immediate sector‑wide shift.

Focused on New Jersey and Georgia markets; limited broader regional effect.

Minimal global impact; primarily a U.S. healthcare niche.

Counterpoint

The plan rollout may strain margins if premium discounts erode profitability, outweighing enrollment gains.

Key entities

  • Clover Health Investments, Corp.

    NASDAQ‑listed provider of Medicare Advantage plans and health‑tech platform.

  • Jamie Reynoso

    CEO of Medicare Advantage at Clover Health, quoted on plan strategy.

Related articles

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$CLOVHigh

Clover Health (CLOV) Gets New ‘Buy’ Call, Higher PT, Climbs 8.5%

Clover Health (CLOV) shares rose 8.53% to $4.71 after Deutsche Bank initiated coverage with a 'buy' rating and $6 price target, citing growth potential in Medicare Advantage and its technology platform. The company reported Q2 net income of $28M, up from a $10.6M loss YoY, with revenues increasing 55.6% to $743.2M. Medicare Advantage membership grew 48% to 157,309. Clover raised its net income and revenue guidance for the year. Hedge fund holdings in CLOV increased fourfold to $79.06M.

$CLOVMed

Clover Health (CLOV) Shares Skyrocket, What You Need To Know

Clover Health (CLOV) shares rose 8.5% after Deutsche Bank initiated coverage with a Buy rating and $6.00 price target, citing growth in Medicare Advantage, its Clover Assistant platform, and its risk model. The stock has seen high volatility, with a 24.2% drop last year due to disappointing earnings and lowered guidance. CLOV is up 96.9% YTD but trades 12.3% below its 52-week high.

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

$CLOVHighAI 8/10

Clover Health (CLOV) Turns Profitable As Medicare Membership Explodes

Clover Health (CLOV) reported Q2 2026 net income of $28M, reversing a $10.6M loss from the prior year. Medicare Advantage membership grew 48% YoY to 157,309. Revenue rose 55.6% to $743.2M, and adjusted EBITDA more than doubled. The company raised its full-year guidance, including adjusted EBITDA to $70M-$85M and GAAP net income to $20M-$35M. Cash and investments increased 13.8% YoY to $443.0M.